Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
Stroke Rehabilitation: Early High-Intensity Therapy FindingsKey Highlights High-intensity therapy within 2.
TRPM8 Cold Sensation Mechanism Explained for Pain CareQuick Summary TRPM8 ion channel converts.
Gum Recession from Snus Confirmed, Caries Risk DebatedKey Highlights Snus use is strongly.
Hypertensive Disorders of Pregnancy: Role of Daily ActivityKey Points Summary Limiting sedentary time.
Climate Change Drives Dengue Outbreaks GloballyKey Takeaways Extreme weather significantly increases.
Teen Driving Risks: Parents Underestimate Safety ThreatsKey Takeaways Teen driving risks remain.
PFK Enzyme Dual Role in Metabolism and Cell CycleKey Highlights Phosphofructokinase (PFK Enzyme) shows.
Exercise During Chemotherapy Supports Brain HealthKey Points Summary A nationwide clinical.
Invasive Cosmetic Procedures Raise Patient Safety ConcernsKey Summary Experts publishing in The.
Oligometastatic Pancreatic Cancer: New Global ConsensusKey Points Summary An international expert.
Leave a Comment